Form 4: PLUS THERAPEUTICS CEO Awarded Future Equity

PLUS THERAPEUTICS, INC. CEO Marc H. Hedrick was granted future stock options and restricted stock units totaling over 7.6 million shares, vesting over three to four years.

Summary

• Marc H. Hedrick, the Chief Executive Officer and a Director of PLUS THERAPEUTICS, INC. (PSTV), was granted derivative securities.
• The grants include 5,748,506 stock options with an exercise price of $0.5744 per share.
• These stock options will vest over four years in equal 1/48th monthly increments, starting from the issuance date of August 13, 2025, and will expire on August 12, 2035.
• Additionally, 1,916,168 Restricted Stock Units (RSUs) were awarded.
• The RSUs will vest over three years: 1/3rd on the first anniversary of the August 13, 2025 grant date, and the remaining 2/3rds in equal monthly installments over the subsequent two years.
• The RSUs convert into common stock on a one-for-one basis upon vesting.
• The total number of underlying shares from these grants is 7,664,674.
• The transaction is reported as made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The grant of significant equity awards to the CEO is generally a positive signal of long-term commitment and incentive alignment, although it introduces potential future dilution.

Positives

• Aligns the CEO's long-term interests with shareholder value through significant equity grants.
• Provides strong incentives for the CEO to drive company performance over multi-year vesting periods.
• The use of a Rule 10b5-1 plan indicates a pre-planned, structured approach to executive compensation.

Negatives

• Potential future dilution for existing shareholders as options are exercised and RSUs vest and convert into common stock.

Risks

• Future dilution from the exercise of stock options and conversion of RSUs could impact earnings per share and stock price.
• The effectiveness of these long-term incentives depends on the company's ability to achieve performance targets that make the options and RSUs valuable.

Future Outlook

The grants are structured to incentivize the CEO's long-term commitment and performance, with vesting schedules extending up to four years for options and three years for RSUs, aligning future compensation with company growth.

Industry Context

NA

Corporate Governance

Related Party Transactions

• Grant of stock options and restricted stock units to Marc H. Hedrick, the Chief Executive Officer and a Director of PLUS THERAPEUTICS, INC.

Stakeholder Impact

• Shareholders: Potential for future dilution from the exercise of options and conversion of RSUs, but also benefit from enhanced management incentive alignment.
• Employees: Reflects standard executive compensation practices, potentially setting a precedent for other long-term incentive programs.

Next Steps

• Vesting of 5,748,506 stock options over four years in monthly increments starting August 13, 2025.
• Vesting of 1,916,168 Restricted Stock Units (RSUs) with 1/3rd vesting on August 13, 2026, and the remaining 2/3rds vesting monthly over the subsequent two years.

Key Dates

Keywords

PLUS THERAPEUTICS, PSTV, Marc H. Hedrick, CEO, Director, Stock Option, Restricted Stock Units, RSU, Equity Grant, Executive Compensation, SEC Form 4, Insider Transaction, 10b5-1 Plan